A Phase 1 interventional study of Nintedanib and Nintedanib in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-05.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To establish the bioequivalence of 1 soft gelatine capsule containing 200 mg nintedanib compared to 2 soft gelatine capsules containing 100 mg nintedanib
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nintedanib, 1 capsule, oral with 240 mL of water
Drug: Nintedanib
Nintedanib, 2 capsules, oral with 240 mL of water
Drug: Nintedanib
Nintedanib, 2 capsules, oral with 240 mL of water
Drug: Nintedanib
1 soft gelatine capsule, single dose, oral
Nintedanib, 2 soft gelatine capsules, single dose, oral
Also known as: Nintedanib, 2 soft gelatine capsules, single dose, oral
AUC0-tz
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference treatment 1 (R1) and Reference treatment 2 (R2) separately.
Time frame: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.
Cmax
Maximum measured concentration of the analyte in plasma (Cmax). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately.
Time frame: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.
AUC0-inf
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately.
Time frame: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.
| Milestone | Nin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T) | Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2) | Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2) |
|---|---|---|---|
| Started | 23 | 23 | 24 |
| Completed | 23 | 23 | 24 |
| Not completed | 0 | 0 | 0 |
| Milestone | Nin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T) | Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2) | Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2) |
|---|---|---|---|
| Started | 23 | 23 | 24 |
| Completed | 23 | 23 | 24 |
| Not completed | 0 | 0 | 0 |
| Milestone | Nin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T) | Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2) | Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2) |
|---|---|---|---|
| Started | 23 | 23 | 24 |
| Completed | 23 | 23 | 24 |
| Not completed | 0 | 0 | 0 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference treatment 1 (R1) and Reference treatment 2 (R2) separately.
| ng*h/mL | Nintedanib, Test Treatment (T) | Nintedanib, Reference Treatment (R1) | Nintedanib, Reference Treatment (R2) |
|---|---|---|---|
| AUC0-tz | 300 ± 38.8 | 310 ± 37.6 | 306 ± 36.2 |
Maximum measured concentration of the analyte in plasma (Cmax). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately.
| ng/mL | Nintedanib, Test Treatment (T) | Nintedanib, Reference Treatment (R1) | Nintedanib, Reference Treatment (R2) |
|---|---|---|---|
| Cmax | 39.3 ± 56.0 | 41.1 ± 43.4 | 39.8 ± 46.3 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately.
| ng*h/mL | Nintedanib, Test Treatment (T) | Nintedanib, Reference Treatment (R1) | Nintedanib, Reference Treatment (R2) |
|---|---|---|---|
| AUC0-inf | 311 ± 38.8 | 322 ± 37.7 | 319 ± 36.4 |
Collected over From first drug administration until 12 days after the last drug administration of nintedanib, ie., upto 16 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib, Test Treatment (T) | — | 0/70 (0%) | 24/70 (34.3%) |
| Nintedanib, Reference Treatment (R1 & R2) | — | 0/70 (0%) | 29/70 (41.4%) |
| Event | Nintedanib, Test Treatment (T) | Nintedanib, Reference Treatment (R1 & R2) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 16/70 | 20/70 |
| HeadacheNervous system disorders | 7/70 | 7/70 |
| NauseaGastrointestinal disorders | 4/70 | 6/70 |
| NasopharyngitisInfections and infestations | 2/70 | 4/70 |
Treated Set (TS): This analysis set included all 70 subjects (that is, all subjects who received at least 1 dose of study medication).
| Age, Continuous(Years) | Nin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T) | Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2) | Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2) | Total |
|---|---|---|---|---|
| Mean | 34.0 ± 10.3 | 36.6 ± 9.5 | 31.6 ± 7.2 | 34.0 ± 9.2 |
| Gender(Participants) | Nin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T) | Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2) | Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2) | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 23 | 23 | 24 | 70 |
The record gives a start of Aug 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib